Guardant Health Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $2.42 billion
- Book Value:
- Revenue TTM:
- $449.54 million
- Operating Margin TTM:
- Gross Profit TTM:
- $293.21 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Guardant Health Inc had its IPO on 2018-10-04 under the ticker symbol GH.
The company operates in the Healthcare sector and Diagnostics & Research industry. Guardant Health Inc has a staff strength of 1,793 employees.
Shares of Guardant Health Inc opened at $23.23 at the start of the last trading session i.e. 2023-03-31.
The stocks traded within a range of $23.17 - $23.88, and closed at $23.44.
This is a +2.27% increase from the previous day's closing price.
A total volume of 2,099,762 shares were traded at the close of the day’s session.
In the last one week, shares of Guardant Health Inc have slipped by -4.25%.
Guardant Health Inc's Key Ratios
Guardant Health Inc has a market cap of $2.42 billion, indicating a price to book ratio of 25.9492 and a price to sales ratio of 9.8119.
In the last 12-months Guardant Health Inc’s revenue was $449.54 million with a gross profit of $293.21 million and an EBITDA of $-508416000. The EBITDA ratio measures Guardant Health Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Guardant Health Inc’s operating margin was -121.1% while its return on assets stood at -17.84% with a return of equity of -185.65%.
In Q4, Guardant Health Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 17.4%.
Guardant Health Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-6.06 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Guardant Health Inc’s profitability.
Guardant Health Inc stock is trading at a EV to sales ratio of 11.0092 and a EV to EBITDA ratio of -8.5917. Its price to sales ratio in the trailing 12-months stood at 9.8119.
Guardant Health Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.61 billion
- Total Liabilities
- $193.22 million
- Operating Cash Flow
- $70.63 million
- Capital Expenditure
- $10.00 million
- Dividend Payout Ratio
Guardant Health Inc ended 2023 with $1.61 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.61 billion while shareholder equity stood at $60.18 million.
Guardant Health Inc ended 2023 with $0 in deferred long-term liabilities, $193.22 million in other current liabilities, 1000.00 in common stock, $-1662413000.00 in retained earnings and $3.29 million in goodwill. Its cash balance stood at $141.65 million and cash and short-term investments were $1.01 billion. The company’s total short-term debt was $21,878,000 while long-term debt stood at $1.14 billion.
Guardant Health Inc’s total current assets stands at $1.19 billion while long-term investments were $0.00 and short-term investments were $869.58 million. Its net receivables were $97.26 million compared to accounts payable of $68.91 million and inventory worth $51.60 million.
In 2023, Guardant Health Inc's operating cash flow was $70.63 million while its capital expenditure stood at $10.00 million.
Comparatively, Guardant Health Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Guardant Health Inc stock is currently trading at $23.44 per share. It touched a 52-week high of $77.72 and a 52-week low of $77.72. Analysts tracking the stock have a 12-month average target price of $58.56.
Its 50-day moving average was $28.41 and 200-day moving average was $41.95 The short ratio stood at 2.62 indicating a short percent outstanding of 0%.
Around 465% of the company’s stock are held by insiders while 9176.6% are held by institutions.
Frequently Asked Questions About Guardant Health Inc
Similar Industry Stocks (Diagnostics & Research)
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, a suite of advanced analytical technologies to enhance the performance and clinical utility of our portfolio of cancer tests. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Palo Alto, California.